Disability, Anti-CD20 Therapy Drive Serious Infection Risk in MS
Summary
Two large real-world studies show that disability, even when mild, is strongly associated with serious infection in MS, and that anti-CD20 therapy roughly doubles the risk vs other treatments.
Description from Medscape.
Who is covering this
-
Disability, Anti-CD20 Therapy Drive Serious Infection Risk in MS
Two large real-world studies show that disability, even when mild, is strongly associated with serious infection in MS, and that anti-CD20 therapy roughly doubles the risk vs other treatments.
Comments
Comments need JavaScript.